newsIsturisa® continues to show promise in Cushing’s disease24 March 2021 | By Hannah Balfour (European Pharmaceutical Review)New Phase III trial results show 81 percent of Cushing’s disease patients who received Isturisa® (osilodrostat) had sustained normalisation of mean urinary free cortisol levels.